132 related articles for article (PubMed ID: 17016446)
1. Tumor suppressor activity of glucocorticoid receptor in the prostate.
Yemelyanov A; Czwornog J; Chebotaev D; Karseladze A; Kulevitch E; Yang X; Budunova I
Oncogene; 2007 Mar; 26(13):1885-96. PubMed ID: 17016446
[TBL] [Abstract][Full Text] [Related]
2. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
[TBL] [Abstract][Full Text] [Related]
3. Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1/2 pathway and cyclin D1 expression.
Gao QZ; Lu JJ; Liu ZD; Zhang H; Wang SM; Xu H
Asian J Androl; 2008 Jul; 10(4):635-41. PubMed ID: 18097517
[TBL] [Abstract][Full Text] [Related]
4. Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer.
Yan TZ; Jin FS; Xie LP; Li LC
Urol Int; 2008; 81(2):228-33. PubMed ID: 18758226
[TBL] [Abstract][Full Text] [Related]
5. Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase.
Singh SV; Choi S; Zeng Y; Hahm ER; Xiao D
Cancer Res; 2007 Aug; 67(15):7439-49. PubMed ID: 17671214
[TBL] [Abstract][Full Text] [Related]
6. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of ligand-dependent down-regulation of glucocorticoid receptor by lipopolysaccharide.
Hirasawa N; Yashima K; Ishihara K
Life Sci; 2009 Oct; 85(15-16):578-85. PubMed ID: 19729027
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Ca2+-independent phospholipase A2 decreases prostate cancer cell growth by p53-dependent and independent mechanisms.
Sun B; Zhang X; Talathi S; Cummings BS
J Pharmacol Exp Ther; 2008 Jul; 326(1):59-68. PubMed ID: 18441250
[TBL] [Abstract][Full Text] [Related]
9. Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells.
Wang P; Ma Q; Luo J; Liu B; Tan F; Zhang Z; Chen Z
Cancer Invest; 2009 May; 27(4):369-75. PubMed ID: 19266349
[TBL] [Abstract][Full Text] [Related]
10. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
11. The mechanisms of tumor suppressor effect of glucocorticoid receptor in skin.
Chebotaev D; Yemelyanov A; Budunova I
Mol Carcinog; 2007 Aug; 46(8):732-40. PubMed ID: 17538956
[TBL] [Abstract][Full Text] [Related]
12. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2.
Tsui KH; Hsieh WC; Lin MH; Chang PL; Juang HH
Prostate; 2008 May; 68(6):610-9. PubMed ID: 18196550
[TBL] [Abstract][Full Text] [Related]
13. Signal regulatory protein alpha1 is involved in the inhibitory effect of glucocorticoid receptor on the proliferation of murine macrophage RAW264.7 cell and mouse peritoneal macrophage.
Wang X; Li Y; Zhu X; Wang Y; Diao F; Lu J
J Mol Endocrinol; 2008 Nov; 41(5):393-403. PubMed ID: 18728125
[TBL] [Abstract][Full Text] [Related]
14. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
Yu S; Wang X; Ng CF; Chen S; Chan FL
Cancer Res; 2007 May; 67(10):4904-14. PubMed ID: 17510420
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells.
Yano A; Fujii Y; Iwai A; Kawakami S; Kageyama Y; Kihara K
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6012-7. PubMed ID: 17062674
[TBL] [Abstract][Full Text] [Related]
16. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
17. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells.
Fang J; Zhou Q; Shi XL; Jiang BH
Carcinogenesis; 2007 Mar; 28(3):713-23. PubMed ID: 17065200
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304
[TBL] [Abstract][Full Text] [Related]
19. The p38 MAPK pathway mediates aryl propionic acid induced messenger rna stability of p75 NTR in prostate cancer cells.
Quann EJ; Khwaja F; Djakiew D
Cancer Res; 2007 Dec; 67(23):11402-10. PubMed ID: 18056468
[TBL] [Abstract][Full Text] [Related]
20. Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation.
Tsai CY; Lee TS; Kou YR; Wu YL
J Cell Biochem; 2009 Oct; 108(2):489-98. PubMed ID: 19626664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
